

A Review on Clinicopathological Correlation between Classical Inflammatory Bowel Disease and Immunotherapy Related Inflammatory Bowel Disease

Timothy R Allen* and Gundrajakuppam Lavanya

Global Allied Pharmaceuticals 160 Vista Oak Dr. Longwood, FL 32779, USA

Abstract

Blockade of various immune targets such as cytotoxic T-lymphocyte antigen-4 and Programmed cell death leads to immune-mediated tumor regression and immune-related adverse events, predominantly gastrointestinal events including diarrhea and colitis. The current review is done to understand the underlying mechanism of action and to identify potential biomarkers that could help in the prediction and management of gastrointestinal immune-related adverse events. Histological assessment of bowel biopsies and assessment of serologic markers of inflammatory bowel disease and colitis secondary to immune mediated antibodies are reviewed. Ipilimumab causes dysregulation of gastrointestinal mucosal immunity, which can be evidenced by altered antibody levels to enteric flora and inflammatory cell infiltration into gastrointestinal mucosa associated with diarrhea and clinical evidence of colitis. The pattern of drug induced antibody titers to microbial flora and the histological features and location of the inflammation were distinct from classic inflammatory bowel disease. Although classic inflammatory bowel disease and immune mediated antibodies related gastrointestinal toxicity are both immune mediated, the pattern of biomarkers and histological features suggests that the later may be a distinct clinicopathological entity.

Keywords: Inflammatory bowel disease; Crohn's disease; ulcerative colitis; GI irAEs; Serological markers

Abbreviations: TAAs: Tumor Associated Antigens; GI: Gastrointestinal; IBD: Inflammatory Bowel Disease; CD: Crohn's Disease; UC: Ulcerative Colitis; CTLA-4: Cytotoxic T-Lymphocyte Antigen-4; IL: Interleukin; irAEs: Immune Related Adverse Events; NOD2: Nucleotide Oligomerization Binding Domain 2; ATG16L: Autophagy Related 16 like; IRGM: Immunity – related GTPase M; HLA: Human Leukocyte Antigen; ADCC: Antibody Dependent Cell-Mediated Cytotoxicity; ADL: Activities of Daily Living; pANCA: Perinuclear-staining Anti-neutrophil Cytoplasmic Antibody; ASCA: Anti-Saccharomyces Cerevisiae Antibody; Anti I2=Antibodies to Bacterial Protein which is a T cell Super Antigen; OmpC: *Escherichia coli* outer membrane porin; CBir1: CBirflagellin Antibody

Introduction

Immunotherapy treatment for cancer was first considered in practice by William Coley who proposed active immunizations (later known as Coley toxins) of cancer patients in the late 19th century [1]. Immunization strategies were followed several decades later by the discovery and clinical application of recombinant immune cell signaling proteins such as interleukin-2 [2]. Most recently, both preclinical and clinical evidence has affirmed a long held hypothesis that tumors inhibit functionality of immune infiltrate and that this process is at least partially reversible through direct blockade of negative regulatory signaling through a class of cell-surface signaling proteins known as checkpoint modulators which include Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) & Programmed Death 1 (PD-1) pathways [3,4].

Components of immunity are seen as potentially more specific weapons to direct against tumors than chemotherapy or radiation [5]. With our expanding knowledge of tumor associated antigens (TAAs), there are many different approaches being developed to direct immunity against transformed cells. Immunotherapies may involve the active generation of immunity to TAA, via vaccination with peptides or peptide-pulsed dendritic cells [6]. In addition, administration of immune modulators, such as cytokines, can boost existing antitumor

immunity and target immune effector cells to sites of tumor growth [7]. Monoclonal antibodies harness both innate and adaptive immune mechanisms and direct them against tumor cells [8]. In addition, the effector functions of cytotoxic T lymphocytes have proven them to be particularly useful in targeting TAA in adoptive immunotherapeutic protocols [9].

Some TAAs are tumor specific, whose expression is entirely limited to tumors, examples of which include viral antigens expressed on cells in which viral oncogenes have contributed to cellular transformation. In these cases, immunotherapy can be used with fine specificity and very little toxicity against normal tissues [10]. However, most TAAs are expressed by some cells of normal tissues and the potential exists for on-target toxicity against these tissues. These on-target toxicities can be assigned to 2 broad categories. First, they can comprise “true” autoimmunity, involving a fundamental induction of endogenous immunity against self-antigens, and we refer to this type as “autoimmunity.” Second, they can be more “drug-like” in nature, where damage is mediated directly by the immunomodulatory agent, and these toxicities are referred to as “immune-mediated”.

There is much promise and excitement in the use of monoclonal antibodies for immunotherapy, with around 10 drugs approved by the Food and Drug Administration for the treatment of cancer [11]. These antibodies are specific for a variety of molecular targets expressed on a range of cancers, including lymphomas, leukemia, breast cancer,

***Corresponding author:** Timothy R Allen, MD, Ph.D, Global Allied Pharmaceuticals 160 Vista Oak Dr. Longwood, FL 32779, USA, Tel: 321-945-4283; E-mail: timallenmed69@gmail.com

Received November 09, 2013; **Accepted** January 10, 2014; **Published** January 17, 2014

Citation: Allen TR, Kuppam LG (2014) A Review on Clinicopathological Correlation between Classical Inflammatory Bowel Disease and Immunotherapy Related Inflammatory Bowel Disease. Immunome Res 10: 074. doi: [10.4172/1745-7580.1000074](https://doi.org/10.4172/1745-7580.1000074)

Copyright: © 2014 Allen TR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

and colorectal cancer. A variety of effector mechanisms are used by antibodies against tumor cells, which include antagonizing growth factors and their receptors, or inducing their degradation. Alternatively, antibodies may activate antibody-dependent cell-mediated cytotoxicity (ADCC) or the complement pathway. Finally, antibodies may also be used to antagonize receptors, such as CTLA-4, which normally down-regulate immune responses. However, just as spontaneously arising tumor-specific antibodies have been shown to induce autoimmune pathologies in paraneoplastic neurologic disorders, toxicities against normal tissues have also been observed in a proportion of patients receiving exogenous antibody [12].

The blockade of CTLA-4 by monoclonal antibodies results in immune-related adverse events (irAEs), including diarrhea and colitis [13]. Examination of colonic biopsies obtained after onset of diarrhea or colitis reveals both acute and chronic inflammation [14]. The etiology of classic inflammatory bowel disease (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), results from dysregulated GI mucosal immunity, possibly related to both genetic susceptibility and an environmental component not yet known but suggested to be related to commensal bacteria [15-17]. Thus, there is an interest in exploring the relationship between GI irAEs resulting from CTLA-4 blockade and classic IBD.

In this review, we discuss the various pathogenetic mechanism, clinical presentations and serological markers associated with IBD and Immunotherapy related colitis, as well as the various differences that can be noted with biopsy and endoscopy.

Inflammatory Bowel Disease

Incidence and prevalence

The highest incidence and prevalence rates for IBD have been reported from northern Europe and North America. In North America, the incidence of UC ranges from 2.2 to 14.3/100,000 person-years and for CD, 3.1 to 14.6/100,000 person-years. The prevalence ranges from 37 to 140/100,000 persons for UC and from 26 to 200/100,000 persons for CD [18,19]. IBD is associated with earlier age of diagnosis (second-fourth decade). Men and women are at similar risk to develop IBD, and there is an increased incidence of IBD in patients those who are of Jewish descent [20].

Pathogenesis

IBD results from a combination of defects in host interactions with intestinal microbiota, intestinal epithelial dysfunction, and aberrant mucosal immune responses.

Genetics

Specific NOD2 polymorphisms confer at least a four-fold increase in CD. NOD2 encodes a protein that binds to intracellular bacterial peptidoglycans and subsequently activates NF- κ B. It has been postulated that disease-associated NOD2 variants are less effective at recognizing and combating luminal microbes, which are then able to enter the lamina propria and trigger inflammatory reactions [21].

Like NOD2, ATG16L1 and IRGM are related to recognition and response to intracellular pathogens, supporting the hypothesis that inappropriate immune reactions to luminal bacteria are an important 18 component of IBD pathogenesis [22]. Polymorphisms of the IL-23 receptor are protective in both CD and UC [23].

Mucosal immune responses

Polarization of helper T cells to the TH1 type is well-recognized in CD and in UC patients. A recent report linking polymorphisms near the IL-10 gene to UC, but not CD [24]. Overall, it is likely that some combination of derangements that activate mucosal immunity and suppress immune regulation contribute to the development of UC and CD.

Epithelial defects

Defects in intestinal epithelial tight junction barrier function are present in CD patients [25]. This barrier dysfunction is associated with NOD2 polymorphisms [26], and experimental models demonstrate that barrier dysfunction can activate innate and adaptive mucosal immunity and sensitize subjects to disease [27]. Defects in the extracellular barrier formed by secreted mucin may also contribute [28]. Interestingly, polymorphisms in ECM1 (extracellular matrix protein 1), which inhibits matrix metalloproteinase 9, are associated with UC but not CD [29]. Finally, the Paneth cell granules, which contain antibacterial peptides termed defensins, are abnormal in CD patients carrying ATG16L1 mutations [30], suggesting that defective epithelial anti-microbial function contributes to IBD.

Microbiota

Despite growing evidence that intestinal microbiota contribute to IBD pathogenesis [31], their precise role remains to be defined and is probably different in UC and CD. Antibodies against the bacterial protein flagellin are associated with NOD2 polymorphisms as well as stricture formation, perforation, and small-bowel involvement in patients with CD, but are uncommon in UC patients. In addition, some antibiotics, e.g. metronidazole, can be helpful in management of CD, and broad-spectrum antibiotics can prevent disease in some experimental models of IBD [32]. One model that unifies the roles of intestinal microbiota, epithelial function, and mucosal immunity suggests a cycle by which transepithelial flux of luminal bacterial components activates innate and adaptive immune responses [33].

Clinical presentation and Endoscopy

CD is often characterized by abdominal pain, weight loss, fatigue, diarrhea with or without gross bleeding and sometimes fever. Fistula formation between the bowel and adjacent organs may have different clinical presentations, including enteroenteric, enterovesical, enterovaginal, and enterocutaneous fistulas [34].

The clinical presentation of patients with UC usually correlates with disease extent and severity [35,36]. Distal colitis refers to colitis extending into the sigmoid colon. Left-sided colitis extends up to the splenic flexure. Pancolitis describes inflammation extending beyond the splenic flexure, even if the inflammation does not reach the caecum. Disease severity is classified as mild, moderate or severe. Mild disease usually manifests as mild diarrhea, tenesmus and intermittent bleeding; moderate disease is characterized by bloody diarrhea (<10 stools per day), abdominal pain and low-grade fever; severe disease is characterized by more significant bloody diarrhea (>10 stools per day), severe abdominal cramping, and high grade fever [37].

IBD is associated with a number of extra intestinal disease manifestations, the mechanisms of these are not completely understood, and may be related to immunologic or non-immunologic processes. The organs most commonly involved include the skin, joints, biliary tract, and eyes, as reviewed elsewhere [38].

Ulcers, ranging from small aphthous ulcers to large, deep or serpigenous ulcers, and discontinuous or skip lesions are common endoscopic findings in CDAs in Figure 1. Mucosal granularity, friability and edema are seen in mild UC, with frank ulceration in moderate to severe cases as in Figure 2.

HPE

Grossly CD may occur in any area of the GI tract, but the most common sites involved at presentation are the terminal ileum, ileocecal valve, and cecum, sparing rectum. The presence of multiple, separate, sharply delineated areas of disease, resulting in skip lesions, is characteristic. Histological examination shows cryptitis, crypt abscess, chronic mucosal damage in the form of architectural distortion, atrophy, and metaplasia and non caseating granulomas. The intestinal wall is thickened as a consequence of transmural edema, inflammation, submucosal fibrosis, and hypertrophy of the muscularis propria, all of which contribute to stricture formation as in Figure 3 [39,40].

Grossly UC involves the rectum and sigmoid and may involve the entire colon. Isolated islands of regenerating mucosa bulge upward to create pseudopolyps. Histological examination shows mucosal inflammation characterized by cryptitis and crypt abscess, ulceration, and chronic mucosal damage. Diffuse, predominantly mononuclear inflammatory infiltrate with plasma cells in the lamina propria is almost universally present as in Figure 4 [41,42].

Serological markers

Atypical P-ANCA and ASCAs are markers for UC and CD, respectively. The combined use of atypical P-ANCA and ASCA test results distinguishes UC from CD in patients with IBD. The P-ANCA+/ASCA- combination is specific for UC, whereas the ASCA+/P-ANCA- combination is specific for CD. There is no relationship between




Figure 1: Serpigenous ulcers in Crohn's disease.



Figure 2: Diffuse ulcers in Ulcerative colitis.




Figure 3: Crypt atrophy with granuloma in CD.




Figure 4: Cryptitis and crypt abscess in UC.

the presence or titer of ANCA and UC activity [43,44]. The ANCA titer remains positive after colectomy [44]. In addition, the presence of ASCAs is stable over time and is independent of CD activity and duration [43,45]. ASCA titers most often remain stable after treatment [45]. Hence, serial measurement of ANCA and ASCA titers in IBD is not useful for follow-up of disease activity and prediction of relapses.

Antibodies against exocrine pancreas have been described in patients with CD, and have been reported to be specific [46,47]. Screening lysates of cultures of colonic bacteria with a monoclonal P-ANCA antibody revealed that *Escherichia coli* outer membrane porin (OmpC) is an antigen in IBD [48]. Landers et al. [49] reported anti-OmpC antibodies in 55% of CD patients. The flagellin CBir1 has been identified as a dominant antigen capable of inducing colitis in C3H/HeJBir mice and eliciting IgG antibody responses in a subpopulation (~50%) of patients with CD [16,50].

Immunotherapy Related Colitis

Incidence and prevalence

Incidence of GI irAEs (e.g. colitis, diarrhea) with ipilimumab 3mg/kg monotherapy was 28.2%, low grade (Grade 1-2) being 20.6% and high grade ((Grade 3-4) being 7.6%. Clinically, the average time of onset of diarrhea was at 6–8 weeks, but can occur as early as 3 days post initiation of treatment with rapid progression to colitis hence early multidisciplinary management is crucial [51].

Pathogenesis

Toxicities arising from antibody administration can occur in various ways. First, toxicity can follow the induction of potent endogenous autoimmunity against both tumor antigens and other self-antigens, resulting in both on- and off-target toxicities. Second, toxicities can involve on-target depletion of normal cell subsets, compromising normal tissue function [5]. CTLA-4 is a regulatory molecule expressed by T cells that transmits an inhibitory signal to T cells on binding to CD80 and CD86 on antigen-presenting cells. The targeting of this inhibitory receptor in immunotherapy has been used to break immune tolerance of T cells to TAAs, resulting in the expansion of T cells that elicit antitumor effects. However, in addition to tumor regression, anti-CTLA-4 antibodies, such as ipilimumab and tremelimumab, have been associated with autoimmunity affecting tissues, including the thyroid, lung, joints, gastric mucosa, and liver.

Of significant interest is that autoimmunity has been demonstrated to be associated with clinical response, suggesting that the greater the immune dysregulation mediated by anti-CTLA-4, the greater the antitumor effect [52]. The delivery of exogenous antibody specific for TAA expressed on both tumor and normal tissue can result in damage to normal tissue mediated by complement or ADCC mediated by innate immune cells, such as macrophages.

Genetic knock-out of CTLA-4 in mice results in diffuse infiltration of inflammatory immune cells into multiple organs due to peripheral T-cell proliferation especially skin and GIT (53). Not surprisingly, blockade of CTLA-4 by monoclonal antibodies results in immune-related adverse events (irAEs), including diarrhea and colitis [13].

In a study, association with worst-grade GI irAE was studied for 20 genetic polymorphisms in 10 immune-related genes. No Cancer Immunity polymorphism exhibited a statistically significant departure from Hardy-Weinberg equilibrium. No association between genotype and worst-grade GI irAE was observed for any of the 18 polymorphisms analyzed. Possible associations with GI irAEs were analyzed for each allele separately. For HLA-A and -B, four and seven alleles, respectively, were carried by at least 10% of all treated subjects with HLA data. No associations between HLA-A or HLA-B allele carrier status and worst-grade GI irAE were observed [53].

Blockade of CTLA-4 by ipilimumab induced fluctuations in the levels of one or more of enteric flora related antibodies. The levels of antibody could exhibit increases, decreases, or both during the induction phase with similar degrees of fluctuation for enteric flora related antibodies [54].

HPE

Biopsies revealed active colitis characterized by marked lamina propria mixed inflammatory cell infiltrates consisting of neutrophils, lymphocytes, plasma cells, and eosinophils. Foci of neutrophilic cryptitis, crypt abscesses, glandular destruction, and erosions of the mucosal surface were evident as in Figures 5 and 6. Ulceration was noted occasionally. Inflammatory changes were diffuse in 75% of the biopsies. There was no meaningful increase in the number of intraepithelial lymphocytes or apoptotic activity in colonocytes. Histologic evidence of chronicity, such as crypt architectural distortion, basal plasmacytosis, granuloma, Paneth cell metaplasia, or pyloric metaplasia, was not evident [55].

Clinical presentation

Most common site for immunotherapy induced GI toxicity is the

lower GI tract. Most common presentation is mild to severe diarrhea or colitis with occasional bloody stools. Diarrhea can be graded based on the severity. GRADE 1 is Increase of < 4 stools per day over baseline and mild increase in ostomy output compared with baseline. GRADE 2 is increase of 4-6 stools per day over baseline; IV fluids are indicated in < 24 hrs; moderate increase in ostomy output compared to baseline; not interfering with ADL. GRADE 3 is increase of ≥ 7 stools per day over baseline; incontinence; IV fluids ≥ 24 hrs; hospitalization; severe increase in ostomy output compared to baseline; interfering with ADL. GRADE 4 is life-threatening consequences (eg. hemodynamic collapse). GRADE 5 is Death. The image from the endoscopy examination shows edema in the bowel and ulcerations in the descending colon as in Figure 7 [55].




Figure 5: Erosion of mucosa, mixed inflammatory infiltrate in lamina propria and crypt abscess.




Figure 6: Erosion of mucosa, mixed inflammatory infiltrate in lamina propria and crypt abscess.



Figure 7: Bowel edema and ulcer in descending colon.

It can rarely lead to gastrointestinal perforation in less than 1% of cases. However in most of the GI irAEs were reversible using product-specific treatment guidelines including vigilant follow-up and early use of steroids when appropriate. Opiates can mask symptoms of perforation and infliximab should not be used in cases of bowel perforation.

Serological markers

In a study, the most common positive antibody titers were to the perinuclear-staining anti-neutrophil cytoplasmic antibody (pANCA) and OmpC (*E. coli*). No strong associations between a positive level and GI irAEs were observed. Most subjects who were positive for anti-I2, anti-Saccharomyces cerevisiae antibody (ASCA), or CBir1 flagellin antibody (CBir1) did not have any grade GI irAE, while approximately 50% of subjects positive for pANCA or OmpC had at least a grade 1 GI irAE [56].

In subjects with grade 2 or higher GI irAEs, the highest frequency of patients with positive titers were seen with anti-pANCA (21.4%) and anti-OmpC (40.5%), with <10% of patients positive for anti-I2, anti-ASCA, and anti-CBir1.

Discussion

Immunotherapy most frequently results in GI and skin irAEs because these are the sites that are exposed to the commensal flora [57]. Blockade of CTLA-4 will result in dysregulation of GI mucosal immunity as evidenced by fluctuating antibody titers to enteric flora, increased levels of neutrophil-derived fecal calprotectin, and inflammatory infiltration into the mucosa. However, the pattern of GI-specific serological markers and histopathological changes are distinct from those observed for classic IBD.

Development of antibodies to enteric flora is an evidence of a dysregulated mucosal immune environment in IBD but not acute (diverticulitis/infection) inflammation [58]. However, antibody positivity to enteric flora is also observed in GI irAEs is not consistent with that for classic IBD. In CD, approximately half of patients are positive for ASCA, anti-CBir1, and anti-I2, anti-OmpC and less than 25% are positive for pANCA, in UC, approximately half of patients are positive for pANCA, but less than 10% are positive for ASCA, anti-CBir1, anti-I2, and anti-OmpC [59]. In GI irAEs more than half of patients with grade 2 or higher irAEs were positive to pANCA and anti-OmpC, with less than 10% of patients positive for anti-I2 and ASCA, and <15% positive for anti-CBir1. Therefore, in GI irAEs, like UC pANCA were positive in approximately 50% of cases, like CD anti-OmpC were positive in approximately 50% of cases. Antibody titers observed in GI irAEs were fluctuating, whereas titers CD are stable over time and with change in disease activity [49]. This fluctuation may reflect changes in the state of T-cell activation as drug concentrations cross an unidentified threshold.

In GI irAEs the location and histological features of the lesion were different from classical IBD [56]. The predominantly diffuse nature of the active inflammation in colonic biopsies from patients after onset of diarrhea are similar to CD, but without granulomas, fissuring ulcers, and bowel wall thickening which are characteristic of CD. Like UC distal colon is frequently involved, but features of chronicity and diffuse colonic involvement distally, which are hallmarks of UC were not observed. Even though cryptitis, crypt abscess present in GI irAEs, chronic mucosal changes like crypt architecture distortion, loss of mucosal goblet cells and paneth cell metaplasia, which is characteristic of classical IBD, is not seen in GI irAEs [60-63]. Finally, the histologic

findings observed here were also distinct from graft-vs.-host disease, which is characterized by prominent epithelial apoptosis and glandular destruction [64].

Like in classical IBD biomarkers to reliably predict which patients would develop, GI irAEs were not identified. Immune cell infiltration of the bowel mucosa early in treatment is suggested to be associated with later onset of colitis but is not reliable enough for routine use. No association between abnormal endoscopic findings and colitis were observed, possibly due to the lower sensitivity. Neutrophil-derived fecal calprotectin, a biomarker of active IBD [64,65] increases upon immunotherapy, indicating active inflammation in the bowel wall but cannot be used to predict onset of any irAE. No associations between GI irAEs and any of 18 single nucleotide polymorphisms (SNPs) in 10 immune-related genes were observed, despite previously reported association of CTLA-4 polymorphisms with autoimmune disease [66].

Conclusion

Immunotherapy is now increasingly used as an effective therapy against tumors; however, it is prone to immune toxicities. Immunotherapy will result in dysregulation of GI mucosal immunity, as this is one of those sites where it is exposed to plenty of commensal flora. The pattern of GI mucosal dysregulation, in GI irAEs evidenced by histology and antibodies to enteric flora, was distinct from that observed for classical IBD, suggesting that diarrhea and colitis due to GI irAEs may represent a distinct clinicopathologic entity which can be treated by drug withdrawal, systemic steroids and infliximab.

Conflict of Interest

This paper has been written without external financial funding. There is no conflict of interest.

Acknowledgments

None declared

References

1. Coley WB (1896) Further observations upon the treatment of malignant tumors with the toxins of erysipelas and *Bacillus prodigiosus* with a report of 160 cases. *John Hopkins Hospital Bulletin* 7:175.
2. Liao W, Lin JX, Leonard WJ (2013) Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. *Immunity* 38: 13-25.
3. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. *Annu Rev Immunol* 25: 267-296.
4. Mocellin S, Benna C, Nitti D (2013) Coinhibitory molecules in cancer biology and therapy. *Cytokine Growth Factor Rev* 24: 147-161.
5. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, et al. (2011) Autoimmunity associated with immunotherapy of cancer. *Blood* 118: 499-509.
6. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. *Nat Rev Immunol* 5: 296-306.
7. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y (2004) Cytokines in cancer immunity and immunotherapy. *Immunol Rev* 202: 275-293.
8. Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. *Lancet* 373: 1033-1040.
9. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. *Curr Opin Immunol* 21: 233-240.
10. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, et al. (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr Virus_ Hodgkin's disease. *J Exp Med* 200: 1623-1633.
11. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nat Rev Immunol* 10: 317-327.

12. Roberts WK, Darnell RB (2004) Neuroimmunology of the paraneoplastic neurological degenerations. *Curr Opin Immunol* 16:616-622.
13. O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. *Cancer* 110: 2614-2627.
14. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, et al. (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. *J Clin Oncol* 24: 2283-2289.
15. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, et al. (2004) Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. *Gastroenterology* 126: 414-424.
16. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, et al. (2005) Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. *Gastroenterology* 128: 2020-2028.
17. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 448: 427-434.
18. LoftusEV Jr. (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 126: 1504-1517.
19. Loftus EV Jr, Schoenfeld P, Sandborn WJ (2002) The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. *Aliment PharmacolThera* 16: 51-60.
20. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, et al. (1998) Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. *Gastroenterology* 114: 1161-1168.
21. Cho JH, Weaver CT (2007) Recent insights into the genetics of inflammatory bowel disease. *Gastroenterology* 133: 1327.
22. The Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447: 661.
23. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, et al. (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 314: 1461.
24. Franke A, Balschun T, Karlsen TH, Svantoraityte J, Nikolaus S, et al. (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. *Nat Genet* 40: 1319.
25. Turner JR (2006) Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. *Am J Pathol* 169: 1900-1901.
26. Buhner S, Buning C, Genschel J, Kling K, Herrmann D, et al. (2006) Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? *Gut* 55: 342-347.
27. Su L, Turner, JR ((2007)) Got guts? Need nerve! *Gastroenterology* 132: 1615-1618.
28. An G, Wei B, Xia B, McDaniel JM, Ju T, et al. (2007) Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. *J Exp Med* 204: 1417-1429.
29. Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, et al. (2008) Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. *Nat Genet* 40: 710-712.
30. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, et al. (2008) A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. *Nature* 13: 259-263.
31. Sartor RB (2008) Microbial influences in inflammatory bowel diseases. *Gastroenterology* 134:577-594.
32. Kang SS, Bloom SM, Norian LA, Geske MJ, Flavell RA, et al. (2008) An antibiotic-responsive mouse model of fulminant ulcerative colitis. *PLoS Med* 5: e41.
33. Biliboni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, et al. (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. *Am J Gastroenterol* 100: 1539-1546.
34. Present DH (2003) Crohn's fistula: current concepts in management. *Gastroenterology* 124: 1629-1635.
35. Kamm MA (2002) Review article: maintenance of remission in ulcerative colitis. *Aliment Pharmacol Therap* 4: 21-24.
36. Rizzello F, Gionchetti P, Venturi A, Campieri M (2003) Review article: medical treatment of severe ulcerative colitis. *Aliment PharmacolTherap* 17 Suppl 2: 7-10.
37. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology (2004) General Practice Parameters Committee of the American College of. Ulcerative colitis practiceguidelines in adults (update). *Am J Gastroenterol* 99: 1371-1385.
38. Podolsky DK (2002) Inflammatory bowel disease. *N Engl J Med* 347: 417-429.
39. Day DW, Jass JR, Pric AB (2003) Morson and Dawson's Gastrointestinal Pathology. Oxford: Blackwell.
40. Warren S, Sommers SC (1954) Pathology of regional ileitis and ulcerative colitis. *JAMA* 154: 189-193.
41. Farmer RG, Hawk WA, Turnbull RB Jr. (1968) Regional enteritis of the colon: a clinical and pathologic comparison with ulcerative colitis. *Am J Dig Dis* 13: 501-514.
42. Price AB, Morson B (1975) Inflammatory bowel disease. The surgical pathology of Crohn's disease and ulcerative colitis. *Hum Pathol* 6: 7-29.
43. Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, et al. (1996) Perinuclearantineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. *Gastroenterology* 110: 1810-1819.
44. Reumaux D, Colombel JF, Masy E, Duclos B, Heresbach D, et al. (2000) Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. *Inflamm Bowel Dis* 6: 270-274.
45. Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, et al. (2001) Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. *Inflamm Bowel Dis* 7: 8-15.
46. Stöcker W, Otte M, Ulrich S, Normann D, Finkbeiner H, et al. (1987) Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. *Scand J Gastroenterol* 139: 41-52.
47. Seibold F, Weber P, Jenss H, Wiedmann KH (1991) Antibodies to trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific marker for a subgroup of patients with Crohn's disease. *Gut* 32: 1192-1197.
48. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, et al. (2000) Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. *Infect Immun* 68: 1542-1548.
49. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, et al. (2002) Selected loss of tolerance evidenced by Crohn's disease-associated immune response to auto- and microbial antigens. *Gastroenterology* 123: 689-699.
50. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, et al. (2004) Bacterial flagellin is a dominant antigen in Crohn disease. *J Clin Invest* 113: 1296-1306.
51. Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. *Oncologist* 12: 864-872.
52. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. *Proc Natl Acad Sci USA* 100: 8372-8377.
53. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, et al. (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity* 3: 541-547.
54. Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, et al. (2009) Melan-Aspecific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. *Clin Cancer Res* 15: 2507-2513.
55. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, et al. (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. *Ann Surg Oncol* 12: 1005-1016.
56. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, et al. (2010) Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. *Cancer Immunology* 10: 11.

57. Weber J, Thompson JA, Hamid O, Minor D, Amin A, et al. (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. *Clin Cancer Res* 15: 5591-5598.
58. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, et al. (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 19: 5-36.
59. Beaven SW, Abreu MT (2004) Biomarkers in inflammatory bowel disease. *Curr Opin Gastroenterol* 20: 318-327.
60. Geboes K (2003) Histopathology of Crohn's disease and ulcerative colitis. In: *Inflammatory bowel disease* (4th ed). Satsangi J, Sutherland LR (Eds.) Edinburgh, London, Churchill Livingstone Elsevier 255-276.
61. Guindi M, Riddell RH (2004) Indeterminate colitis. *J ClinPathol* 57: 1233-1244.
62. Sands BE (2004) From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. *Gastroenterology* 126: 1518-1532.
63. Shidham VB, Chang CC, Shidham G, Ghazala F, Lindholm PF, et al. (2003) Colon biopsies for evaluation of acute graft-versus-host disease (A-GVHD) in allogeneic bone marrow transplant patients. *BMC Gastroenterol* 3: 5.
64. Konikoff MR, Denson LA (2006) Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. *Inflamm Bowel Dis* 12: 524-534.
65. von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, et al. (2007) Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. *Am J Gastroenterol* 102: 803-813.
66. Ueda H, Howson JM, Esposito L, Heward J, Snook H, et al. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. *Nature* 423: 506-511.

Citation: Allen TR, Kuppam LG (2014) A Review on Clinicopathological Correlation between Classical Inflammatory Bowel Disease and Immunotherapy Related Inflammatory Bowel Disease. *Immunome Res* 10: 074. doi: [10.4172/1745-7580.1000074](https://doi.org/10.4172/1745-7580.1000074)

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 250 Open Access Journals
- 20,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.omicsonline.org/submission>

